Showing results (131-140 of 270) with videos related to
Sort By:
Pageof 27
ESMO Open|April 2, 2020
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspectiveMatteo Lambertini, Angela Toss, Antonio Passaro, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2025
Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor ApproachTaiwo Adesoye, Ecaterina E Dumbrava, Kanwal P S Raghav, et al.Frontiers in Oncology|May 12, 2020
Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO ModelFilippo de Marinis, Ilaria Attili, Stefania Morganti, et al.Journal for Immunotherapy of Cancer|April 9, 2026
Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinomaAmaury Daste, Xiuning Le, Amani Makkouk, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 12, 2024
Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline MutationsKelsey Pan, Jennifer Owens, Yasir Elamin, et al.Development (Cambridge, England)|April 26, 2013
A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma developmentXiuning Le, Emily K Pugach, Simone Hettmer, et al.Lung Cancer (Amsterdam, Netherlands)|September 21, 2020
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancerXiaoke Liu, Lingzhi Hong, Monique Nilsson, et al.Critical Reviews in Oncology/Hematology|April 12, 2026
Epidermal Growth Factor Receptor (EGFR) atypical mutations in Non-Small-Cell Lung Cancer (NSCLC): 'where the streets have no name'Gianluca Spitaleri, Pamela Trillo Aliaga, Gianluca Alessio Mariani, et al.Cancers|July 2, 2021
Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical FeaturesAntonio Passaro, Silvia Novello, Diana Giannarelli, et al.JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.Pageof 27